Image

Diagnosis, Prognosis, and Mechanisms in Panvascular Disease

Diagnosis, Prognosis, and Mechanisms in Panvascular Disease

Recruiting
18-80 years
All
Phase N/A

Powered by AI

Overview

This study aims to establish a standardized cohort for panvascular diseases, encompassing biological materials such as DNA samples, along with extensive patient medical records and follow-up information. The design of this database will enable it to serve as a comprehensive resource for future medical research.

Upon data collection, researchers will conduct various statistical analyses to enhance our understanding of the factors and mechanisms contributing to various panvascular diseases, including coronary heart disease, myocardial infarction, stroke, and peripheral vascular disease. These statistical analyses will also aid in identifying more effective treatment strategies for these conditions.

By amassing a large volume of data from a significant number of patients with panvascular diseases, researchers will be able to perform highly precise analyses of the factors influencing the onset, progression, and treatment of these diseases. The results of these precise analyses can then be utilized to optimize clinical practices for the prevention and treatment of panvascular diseases.

Description

Panvascular diseases are a group of complex disorders affecting the entire vascular system, with their development influenced by multiple risk factors, including genetic susceptibility, metabolic abnormalities (such as hypertension, hyperlipidemia, and diabetes), inflammatory responses, oxidative stress, and unhealthy lifestyle habits (such as smoking and physical inactivity). In-depth research into the mechanisms of these factors can help uncover the core drivers of the disease, providing a theoretical foundation for early prevention and intervention. Additionally, elucidating specific molecular pathways (such as inflammatory signaling, lipid metabolism, and endothelial dysfunction-related pathways) and molecular regulatory mechanisms (such as non-coding RNAs and epigenetic modifications) can offer new targets for precise diagnosis and treatment. By integrating multi-omics data and high-throughput technologies, the molecular networks of panvascular diseases can be systematically clarified, advancing the development of personalized medicine. This will significantly improve patient outcomes, reduce disease burden, and hold substantial scientific value and clinical application prospects.

This study aims to establish a standardized cohort for panvascular diseases, encompassing various biological materials such as DNA samples, as well as comprehensive patient medical records and long-term follow-up information. The database will systematically collect multidimensional data, including patient questionnaire data (e.g., lifestyle, family history, dietary habits), imaging examination results (e.g., ultrasound, CT, MRI), DNA and other biochemical indicators extracted from blood samples, as well as non-invasive physiological parameters such as blood pressure and heart rate, and examinations related to arterial health assessment (e.g., pulse wave velocity, ankle-brachial index). By integrating these multi-source data, researchers will be able to conduct in-depth analyses of the genetic, metabolic, and clinical characteristics of panvascular diseases, identify disease-related biomarkers and predictive factors, and thereby provide a valuable resource for investigating the mechanisms of panvascular diseases.

Based on this database, researchers can systematically explore the risk factors of panvascular diseases and their dynamic evolution patterns, uncovering the key driving mechanisms behind disease development. Furthermore, through high-throughput sequencing, multi-omics analysis, and machine learning technologies, researchers can identify potential molecular targets and therapeutic strategies, advancing the field of precision medicine. These research outcomes will not only contribute to the development of novel diagnostic methods and personalized treatment plans but also provide a scientific basis for the early prevention and intervention of panvascular diseases, ultimately improving patient prognosis and reducing disease burden. The establishment of this resource platform will provide critical support for research and clinical practice in panvascular diseases, holding profound scientific significance and practical value.

Eligibility

Inclusion Criteria:

  1. Male or female aged 18 to 80 years old;
  2. Diagnosed or suspected panvascular disease, defined as the presence of atherosclerotic lesions in at least two or more vascular regions, such as intracranial arteries, carotid arteries, coronary arteries, aorta, and peripheral arteries;
  3. Voluntary participation in this study and provision of signed informed consent.

Exclusion Criteria:

  1. Severe hemodynamic instability;
  2. Severe cardiac dysfunction (EF < 30%);
  3. Severe arrhythmias;
  4. Severe valvular heart disease;
  5. Cardiomyopathy caused by non-coronary artery diseases;
  6. Non-atherosclerotic coronary artery disease (e.g., coronary artery dissection, embolism, etc.);
  7. Severe non-cardiovascular diseases;
  8. Women who are pregnant or breastfeeding;
  9. Individuals who refuse to provide signed informed consent.

Study details
    Panvascular Diseases
    Cardiovascular Diseases

NCT07151183

Jinwei Tian

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.